Cochrane Tamiflu review raises more questions than it answersAnalysis raises several questions about efficacy, safety of oseltamivir in the management of influenza. Investigational drug updateSpotlight on drugs in late-stage development in Canada. New antiretroviral agent added to HIV arsenal Drug News: June 2011 Byetta: second GLP-1 agonist for diabetes; Gilenya: first oral disease-modifying drug for MS; Nucynta CR: new opioid for moderate—moderate/severe pain. Study OKs off-label bevacizumab in macular degeneration Cancer drug much cheaper than similar agent designed for eye diseases Drug offers oral option for MS Unearthing the latest in new drugs A look at novel agents in the late stages of development in Canada. Rheumatoid arthritis biologics may provoke shingles outbreaks Researchers advise clinicians to be vigilant when prescribing anti-TNF therapy A museum visit—the pharmacy way Our writer explores the wonders of early alchemy on a recent trip to Switzerland. Actemra: anaphylaxis risk Hoffmann-La Roche and Health Canada warn about potential risk of fatal anaphylaxis with Actemra (tocilizumab). First Previous 8 9 10 11 12 Next Last
